Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimacimab in obesity
NCT06577090Phase 2Active, not recruiting
- Sponsor
- Skye Bioscience
- Start
- Aug 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimacimab in obesity, sponsored by Skye Bioscience. Started Aug 2024; status: active, not recruiting.
02
Drugs
nimacimab
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06577090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577090.